Around 15% of all breast cancer cases overexpress the human epidermal growth factor receptor 2 (ERBB2 or HER2) and is therefore referred to as HER2+ (HER2 positive) breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.